<?xml version="1.0" encoding="UTF-8"?>
<table id="PMC7059311/table_3" xmlns="http://www.w3.org/1999/xhtml">
 <caption>
  <label>Table 3</label>
  <p>Clinical characteristics of psychiatric patients stratified by achieving SVR-12</p>
 </caption>
 <thead>
  <tr>
   <th colspan="1" rowspan="1" id="0-0-."/>
   <th colspan="1" rowspan="1" id="0-1-.">SVR-12 
    <i>(N = 127)</i>
   </th>
   <th colspan="1" rowspan="1" id="0-2-.">No SVR-12 
    <i>(N = 17)</i>
   </th>
   <th colspan="1" rowspan="1" id="0-3-.">
    <b>
     <i>p-value</i>
    </b>
   </th>
  </tr>
 </thead>
 <tbody>
  <tr>
   <td>
    <b>Sex, males.</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>58 (45.7%)</td>
   <td>13 (76.5%)</td>
   <td>
    <b>0.020</b>
   </td>
  </tr>
  <tr>
   <td>
    <b>Age, years, mean (SD)</b>
   </td>
   <td>61.8 ± 13.3</td>
   <td>51.6 ± 11.7</td>
   <td>
    <b>0.038</b>
   </td>
  </tr>
  <tr>
   <td colspan="4">
    <b>Risk Factors</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>IDU</i>
   </td>
   <td>28 (22.0%)</td>
   <td>9 (52.9%)</td>
   <td>
    <b>0.014</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>Heterosexual</i>
   </td>
   <td>10 (7.9%)</td>
   <td>0</td>
   <td>0.607</td>
  </tr>
  <tr>
   <td>
    <i>MSM</i>
   </td>
   <td>1 (0.8%)</td>
   <td>0</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td> Nosocomial</td>
   <td>36 (28.3%)</td>
   <td>2 (11.8%)</td>
   <td>0.239</td>
  </tr>
  <tr>
   <td>
    <i>Unknown</i>
   </td>
   <td>52 (41.0%)</td>
   <td>6 (35.3%)</td>
   <td>0.794</td>
  </tr>
  <tr>
   <td colspan="4">
    <b>HCV Genotypes</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
  </tr>
  <tr>
   <td>
    <i>1a</i>
   </td>
   <td>27 (21.3%)</td>
   <td>5 (29.4%)</td>
   <td>0.534</td>
  </tr>
  <tr>
   <td>
    <i>1b</i>
   </td>
   <td>45 (35.4%)</td>
   <td>6 (35.3%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td>
    <i>2</i>
   </td>
   <td>35 (27.6%)</td>
   <td>2 (11.8%)</td>
   <td>0.238</td>
  </tr>
  <tr>
   <td>
    <i>3</i>
   </td>
   <td>15 (11.8%)</td>
   <td>3 (17.6%)</td>
   <td>0.448</td>
  </tr>
  <tr>
   <td>
    <i>4</i>
   </td>
   <td>5 (3.9%)</td>
   <td>1 (5.9%)</td>
   <td>0.536</td>
  </tr>
  <tr>
   <td>
    <b>Log 10 HCV-RNA, IU/mL, median (range)</b>
   </td>
   <td>6.00 (5.5–6.5)</td>
   <td>6.1 (5.5–6.7)</td>
   <td>0.841</td>
  </tr>
  <tr>
   <td>
    <b>Liver stiffness, Kpa, mean (SD)</b>
   </td>
   <td>11.1 ± 10.4</td>
   <td>8.9 ± 3.4</td>
   <td/>
  </tr>
  <tr>
   <td>
    <b>Previous failure,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>24 (18.9%)</td>
   <td>8 (47.0%)</td>
   <td>
    <b>0.024</b>
   </td>
  </tr>
  <tr>
   <td>
    <b>INF-based tx</b>
   </td>
   <td>23</td>
   <td>8</td>
   <td/>
  </tr>
  <tr>
   <td>
    <b>DAAs-based tx</b>
   </td>
   <td>1</td>
   <td>0</td>
   <td/>
  </tr>
  <tr>
   <td>
    <b>FIB-4 score median (range)</b>
   </td>
   <td>2.0 (1.4–3.3)</td>
   <td>1.5 (1.3–2.1)</td>
   <td>0.226</td>
  </tr>
  <tr>
   <td>
    <b>APRI score median (range)</b>
   </td>
   <td>0.6 (0.4–1.2)</td>
   <td>0.6 (0.5–1.2)</td>
   <td>0.936</td>
  </tr>
  <tr>
   <td>
    <b>MELD score median (range)</b>
   </td>
   <td>7.0 (6.0–8.0)</td>
   <td>7.0 (6.0–7.0)</td>
   <td>0.794</td>
  </tr>
  <tr>
   <td>
    <b>Cirrhosis,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>40 (31.5%)</td>
   <td>6 (35.3%)</td>
   <td>0.785</td>
  </tr>
  <tr>
   <td>
    <b>Oesophageal varices or portal hypertension,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>13 (10.2%)</td>
   <td>2 (11.8%)</td>
   <td>0.691</td>
  </tr>
  <tr>
   <td colspan="4">
    <b>Type of HCV therapy</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
  </tr>
  <tr>
   <td> SOF + RBV</td>
   <td>7 (5.5%)</td>
   <td>0</td>
   <td>0.594</td>
  </tr>
  <tr>
   <td> SOF + SMV ± RBV</td>
   <td>5 (3.9%)</td>
   <td>0</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td> SOF + LDV ± RBV</td>
   <td>18 (14.2%)</td>
   <td>3 (17.6%)</td>
   <td>0.715</td>
  </tr>
  <tr>
   <td> SOF + DCV ± RBV</td>
   <td>11 (8.7%)</td>
   <td>2 (11.8%)</td>
   <td>0.652</td>
  </tr>
  <tr>
   <td> OMB + PTV/r + DAS ± RBV</td>
   <td>13 (10.2%)</td>
   <td>2 (11.8%)</td>
   <td>0.691</td>
  </tr>
  <tr>
   <td> OMB + PTV/r + RBV</td>
   <td>1 (0.8%)</td>
   <td>1 (5.9%)</td>
   <td>0.222</td>
  </tr>
  <tr>
   <td> SOF + VEL ± RBV</td>
   <td>30 (23.6%)</td>
   <td>7 (41.2%)</td>
   <td>0.141</td>
  </tr>
  <tr>
   <td> GLE + PIB</td>
   <td>24 (18.9%)</td>
   <td>0</td>
   <td>0.076</td>
  </tr>
  <tr>
   <td> GRZ + EBR ± RBV</td>
   <td>18 (14.2%)</td>
   <td>2 (11.8%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td>
    <b>Addition of RBV</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>27 (21.2%)</td>
   <td>6 (35.3%)</td>
   <td>0.222</td>
  </tr>
  <tr>
   <td>
    <b>ALT, UI/L, median (range)</b>
   </td>
   <td>50 (28.5–77.5)</td>
   <td>70 (47–125)</td>
   <td>
    <b>0.031</b>
   </td>
  </tr>
  <tr>
   <td>
    <b>Total bilirubin, mg/dL, median (range)</b>
   </td>
   <td>0.62 (0.44–0.83)</td>
   <td>0.60 (0.40–0.80)</td>
   <td>0.561</td>
  </tr>
  <tr>
   <td>
    <b>Serum creatinine, mg/dL, median (range)</b>
   </td>
   <td>0.79 (0.61–0.95)</td>
   <td>0.78 (0.63–0.80)</td>
   <td>0.928</td>
  </tr>
  <tr>
   <td>
    <b>Platelets (×10^9/L), median (range)</b>
   </td>
   <td>182 (139–219)</td>
   <td>185 (157–210)</td>
   <td>0.920</td>
  </tr>
  <tr>
   <td>
    <b>Patients with at least 1 other comorbidity, n (%)</b>
   </td>
   <td>94 (74%)</td>
   <td>7 (41.2%)</td>
   <td>
    <b>0.009</b>
   </td>
  </tr>
  <tr>
   <td>
    <b>Diabetes,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>18 (14.2%)</td>
   <td>2 (11.8%)</td>
   <td>1.000</td>
  </tr>
  <tr>
   <td>
    <b>Hypertension,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>57 (44.9%)</td>
   <td>4 (23.5%)</td>
   <td>0.119</td>
  </tr>
  <tr>
   <td>
    <b>HIV infected,</b>
    <b>
     <i>n</i>
    </b>
    <b>(%)</b>
   </td>
   <td>17 (13.4%)</td>
   <td>2 (11.8%)</td>
   <td>1.000</td>
  </tr>
 </tbody>
 <tfoot>
  <p>
   <i>Legend</i>: 
   <i>IDU</i> Injecting drug user, 
   <i>MSM</i> Man who have sex with man, 
   <i>INF</i> Interferon, 
   <i>DAA</i> Direct antiviral agent, 
   <i>SOF</i> Sofosbuvir, 
   <i>RBV</i> Ribavirin, 
   <i>SMV</i> Simeprevir, 
   <i>LDV</i> Ledipasvir, 
   <i>DCV</i> Daclatasvir, 
   <i>OMB</i> Ombitasvir, 
   <i>PTV/r</i> Paripatrevir/ritonavir, 
   <i>DSV</i> Dasabuvir, 
   <i>VEL</i> Velpatasvir, 
   <i>GLE</i> Glecaprevir, 
   <i>PIB</i> Pibrentasvir, 
   <i>GRZ</i> Grazoprevir, 
   <i>EBR</i> Elbasvir, 
   <i>ALT</i> Alanine aminotransferase, 
   <i>ART</i> Antiretroviral therapy 
  </p>
 </tfoot>
</table>
